权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Multiparametric ultrasound imaging for early detection of nonalcoholic fatty liver disease

多参数超声成像用于早期检测非酒精性脂肪肝

基本信息

批准号：
10532168
负责人：
Kenneth Hoyt
金额：
$ 40.54万
依托单位：
UNIVERSITY OF TEXAS DALLAS
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-12-21 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10532168
关键词：
Address Affect Basic Science Benign Biological Markers Blood flow Calibration Caring Cicatrix Cirrhosis Clinical Coupling Data Development Diagnosis Discrimination Disease Disease Progression Drug Industry Early Diagnosis Fatty acid glycerol esters Fibrosis Goals Hepatocyte Histologic Human Image Imaging technology Inflammation Life Life Style Modification Link Lipids Liver Liver Fibrosis Liver diseases Lobular Measurement Measures Medical Methods Modeling Monitor Non-Invasive Detection Obesity Epidemic Pathology Patients Pattern Performance Perfusion Pharmaceutical Preparations Pharmacotherapy Prevalence Primary carcinoma of the liver cells Rattus Research Research Project Grants Research Proposals Risk Sampling Errors Severities Staging Surrogate Markers Symptoms System Technology Testing Tissues Ultrasonography United States Validation Viscosity biophysical model chronic liver disease clinical implementation clinical translation comorbidity contrast enhanced cost cost effective data modeling diet and exercise disease diagnosis drug candidate elastography imaging biomarker imaging system in vivo innovation liver biopsy liver imaging liver inflammation liver transplantation non-alcoholic fatty liver disease nonalcoholic steatohepatitis pharmacologic rapid growth simple steatosis ultrasound virtual

项目摘要

PROJECT SUMMARY Liver disease is increasing in numbers and relevance across the globe. This disease causes no noticeable symptoms in many cases. After diagnosis, the costs associated with medical care are very high. Patients can be characterized on the nonalcoholic fatty liver disease (NAFLD) spectrum based on the progressive presence of steatosis (i.e. abnormal accumulation of fat within the liver), inflammation, ballooning, and then hepatic fibrosis. Despite the rapid growth and prevalence, the only therapy to treat NAFLD are lifestyle modifications, such as diet and exercise. While the pharmaceutical industry is actively pursuing the discovery and development of candidate drug therapies to address this unmet medical need, there is an urgent clinical need for the ability to noninvasively detect, accurately stage, and reliably monitor NAFLD. To that end, the goal of this research project is to develop a system and method for multiparametric ultrasound (mpUS) imaging of nonalcoholic fatty liver disease (NAFLD) including early pathology progression. Our preliminary findings strongly suggest that a single mpUS test that combines steatosis, ballooning, and inflammation information has the potential to provide a comprehensive estimation of the main components of early stage NAFLD. The main innovation of the proposed research project lies in the implicit link between biophysical models of NAFLD with these coordinated mpUS measurements. The first objective of this project is to develop an integrated ultrasound system and method for performing mpUS imaging. Then we will optimize this new imaging system in healthy rat liver. Lastly, we will evaluate mpUS imaging with a rat model of NAFLD that mirrors disease progression in humans. Here we will also optimize a biophysical model and longitudinal performance in the decision of NAFLD progression. If successful, this research will introduce and validate a safe, cost-effective mpUS imaging technology that can noninvasively detect, accurately stage, and reliably monitor NAFLD.

项目总结